152. Protective Antibody Levels 7.5 Years After Primary Vaccination in Adolescence With a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings

BACKGROUND: 4CMenB has been shown to be immunogenic with an acceptable safety profile in infants and young adolescents. However, no data on long-term persistence after primary vaccination in adolescents are available. This is the first study to assess antibody persistence, booster response, and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Terry, O’Ryan, Miguel, Santolaya, María Elena, De Looze, Ferdinandus, Marshall, Helen, Richmond, Peter, Henein, Sam, Rheault, Paul, Heaton, Ken, Perrett, Kirsten, Garfield, Hartley, Gupta, Anil, Ferguson, Murdo, D’Agostino, Diego, Toneatto, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252687/
http://dx.doi.org/10.1093/ofid/ofy209.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252687/
http://dx.doi.org/10.1093/ofid/ofy209.022

Ejemplares similares